Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Zanin, Sofia ^a   Borgo, Christian ^a   Girardi, Cristina ^a   O'Brien, Sean E ^b   Miyata, Yoshihiko ^c   Pinna, Lorenzo A ^a,d   Donella Deana, Arianna ^a   Ruzzene, Maria ^a,d  

^a UNIVERSITY OF PADOVA   (Italy)

^b Cylene Pharmaceuticals   (United States)

^c KYOTO UNIVERSITY   (Japan)

^d VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 [(3 ETHYLPHENYL)AMINO]PYRIMIDO[4,5 C]QUINOLINE 8 CARBOXYLIC ACID; ANTINEOPLASTIC AGENT; CISPLATIN; CX 4945; CX 5011; DOXORUBICIN; IMATINIB; PROTEIN CASEIN KINASE II INHIBITOR; PROTEIN KINASE INHIBITOR; SILMITASERTIB; UNCLASSIFIED DRUG; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL DESTRUCTION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE;

APOPTOSIS; CASEIN KINASE II; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; NAPHTHYRIDINES; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINOLINES; VINBLASTINE;

EID: 84869055049     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049193     Document Type: Article

References (44)

1. Salvi M, Sarno S, Cesaro L, Nakamura H, Pinna LA, (2009) Extraordinary pleiotropy of protein kinase CK2 revealed by weblogo phosphoproteome analysis. Biochim Biophys Acta 1793: 847-859.
2. Ahmed K, Gerber DA, Cochet C, (2002) Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol 12: 226-230.
3. Litchfield DW, (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 369: 1-15.
4. Ahmad KA, Wang G, Unger G, Slaton J, Ahmed K, (2008) Protein kinase CK2-a key suppressor of apoptosis. Adv Enzyme Regul 48: 179-187.
5. St-Denis NA, Litchfield DW, (2009) Protein kinase CK2 in health and disease: From birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival. Cell Mol Life Sci 66: 1817-1829.
6. Ruzzene M, Pinna LA, (2010) Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta 1804: 499-504.
7. Duncan JS, Litchfield DW, (2008) Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta 1784: 33-47.
8. Dominguez I, Sonenshein GE, Seldin DC, (2009) Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NF-kappaB signaling: linking development and cancer. Cell Mol Life Sci 66: 1850-1857.
9. Trembley JH, Wang G, Unger G, Slaton J, Ahmed K, (2009) Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci 66: 1858-1867.
10. Trembley JH, Chen Z, Unger G, Slaton J, Kren BT, et al. (2010) Emergence of protein kinase CK2 as a key target in cancer therapy. Biofactors 36: 187-195.
11. Sarno S, Ghisellini P, Pinna LA, (2002) Unique activation mechanism of protein kinase CK2. The N-terminal segment is essential for constitutive activity of the catalytic subunit but not of the holoenzyme. J Biol Chem 277: 22509-22514.
12. Battistutta R, (2009) Protein kinase CK2 in health and disease: Structural bases of protein kinase CK2 inhibition. Cell Mol Life Sci 66: 1868-1889.
13. Sarno S, Papinutto E, Franchin C, Bain J, Elliott M, et al. (2011) ATP site-directed inhibitors of protein kinase CK2: an update. Curr Top Med Chem 11: 1340-1351.
14. Ljubimov AV, Caballero S, Aoki AM, Pinna LA, Grant MB, et al. (2004) Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization. Invest Ophthalmol Vis Sci 45: 4583-4591.
15. Mishra S, Pertz V, Zhang B, Kaur P, Shimada H, et al. (2007) Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2. Leukemia 21: 178-180.
16. Prudent R, Moucadel V, Nguyen CH, Barette C, Schmidt F, et al. (2010) Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2. Cancer Res 70: 9865-9874.
17. Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, et al. (2010) CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 70: 10288-10298.
18. Manni S, Brancalion A, Quotti Tubi L, Colpo A, Pavan L, et al. (2012) Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response. Clin Cancer Res 18: 1888-1900.
19. Battistutta R, Cozza G, Pierre F, Papinutto E, Lolli G, et al. (2011) Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. Biochemistry 50: 8478-8488.
20. Siddiqui-Jain A, Chua P, Darjania L, Lim J, O'Brien S, et al. (2008) The discovery and characterization of CX-5011, a highly selective, potent inhibitor of Protein Kinase CK2. AACR Meeting Abstracts 2008: 4875.
21. Fukuda Y, Schuetz JD, (2012) ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol 83: 1073-1083.
22. Sawicka M, Kalinowska M, Skierski J, Lewandowski W, (2004) A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence. J Pharm Pharmacol 56: 1067-1081.
23. Tew KD, (2012) Drug resistance in cancer. Editorial. Biochem Pharmacol 83: 985-6.
24. Rosenzweig SA, (2012) Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem Pharmacol 83: 1041-1048.
25. Glavy JS, Horwitz SB, Orr GA, (1997) Identification of the in vivo phosphorylation sites for acidic-directed kinases in murine mdr1b P-glycoprotein. J Biol Chem 272: 5909-5914.
26. Stolarczyk EI, Reiling CJ, Pickin KA, Coppage R, Knecht MR, et al. (2012) Casein Kinase 2α (CK2α) Regulates Multidrug Resistance Associated Protein (MRP1) Function Via Phosphorylation of Thr249. Mol Pharmacol Epub ahead of print.
27. Di Maira G, Brustolon F, Bertacchini J, Tosoni K, Marmiroli S, et al. (2007) Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level. Oncogene 26: 6915-6926.
28. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, et al. (2005) Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 12: 668-677.
29. Cenni V, Maraldi NM, Ruggeri A, Secchiero P, Del Coco R, et al. (2004) Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase. Int J Oncol 25: 1599-1608.
30. Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, et al. (2007) Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 42: 872-881.
31. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, et al. (2000) Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95: 1758-1766.
32. Redaelli S, Boschelli F, Perini P, Pirola A, Viltadi M, et al. (2010) Synergistic activity of the Src/Abl inhibitor bosutinib in combination with Imatinib. Leukemia 6: 1223-1227.
33. Ruzzene M, Penzo D, Pinna LA, (2002) Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J 364: 41-47.
34. Ruzzene M, Di Maira G, Tosoni K, Pinna LA, (2010) Assessment of CK2 constitutive activity in cancer cells. Methods Enzymo 484: 495-514.
35. Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M, (2004) Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 10: 2936-2943.
36. Goda K, Bacsó Z, Szabó G, (2009) Multidrug resistance through the spectacle of P-glycoprotein. Curr Cancer Drug Targets 9: 281-297.
37. Bixby D, Talpaz M, (2009) Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program pp. 461-476.
38. Miyata Y, Nishida E, (2005) CK2 binds, phosphorylates, and regulates its pivotal substrate Cdc37, an Hsp90-cochaperone. Mol Cell Biochem 274: 171-179.
39. Meggio F, Donella Deana A, Ruzzene M, Brunati AM, Cesaro L, et al. (1995) Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem 234: 317-322.
40. Ruzzene M, Tosoni K, Zanin S, Cesaro L, Pinna LA, (2011) Protein kinase CK2 accumulation in "oncophilic" cells: causes and effects. Mol Cell Biochem 356: 5-10.
41. Di Maira G, Brustolon F, Tosoni K, Belli S, Krämer SD, et al. (2008) Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis. Mol Cell Biochem 316: 155-161.
42. Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, et al. (2006) Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 108: 1698-1707.
43. Siddiqui-Jain A, Bliesath J, Macalino D, Omori M, Huser N, et al. (2012) CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol Cancer Ther 11: 994-1005.
44. Bliesath J, Huser N, Omori M, Bunag D, Proffitt C, et al. (2012) Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Lett 322: 113-1188.